AI Engines For more Details: Perplexityβ Kagi Labsβ Youβ
Antiviral Action: Acyclovir is a synthetic nucleoside analog of guanosine that selectively inhibits the replication of herpesviruses by interfering with viral DNA synthesis. It exerts its antiviral activity by acting as a substrate for viral DNA polymerase, leading to chain termination and inhibition of viral DNA replication.
Herpes Simplex Infections: Acyclovir is widely used in the treatment of herpes simplex infections, including herpes labialis (cold sores), genital herpes (herpes genitalis), and herpes keratitis (ocular herpes). It helps reduce the severity and duration of acute herpes outbreaks and may also suppress recurrent episodes.
Varicella-Zoster Infections: Acyclovir is also indicated for the treatment of varicella-zoster infections, including chickenpox (varicella) and herpes zoster (shingles). It helps alleviate symptoms such as rash, itching, and pain associated with these viral infections and may reduce the risk of complications such as postherpetic neuralgia.
Topical and Systemic Formulations: Acyclovir is available in various formulations, including oral tablets, capsules, suspension, and topical cream or ointment. Oral formulations are commonly used for systemic treatment of herpes infections, while topical formulations are used for localized lesions such as cold sores or herpes labialis.
Early Initiation of Treatment: Acyclovir is most effective when initiated early in the course of herpes or varicella-zoster infections, ideally within 48 hours of the onset of symptoms. Early treatment helps maximize the antiviral effects of acyclovir and may reduce the severity and duration of the infection.
Suppressive Therapy: In addition to acute treatment of herpes outbreaks, acyclovir may be used for long-term suppressive therapy in individuals with frequent recurrences of genital herpes or those with immunocompromised status. Suppressing viral replication with acyclovir may help reduce the frequency and severity of recurrent episodes.
Safety and Tolerability: Acyclovir is generally well-tolerated when used at recommended doses. Common side effects may include nausea, vomiting, diarrhea, headache, and dizziness. Rare but serious adverse effects such as nephrotoxicity (kidney damage) or neurotoxicity (central nervous system effects) may occur with high doses or prolonged use.
Drug Interactions: Acyclovir may interact with certain medications, particularly those that affect renal function or compete for renal elimination. Concurrent use of nephrotoxic drugs or drugs that interfere with renal tubular secretion may increase the risk of acyclovir toxicity or reduce its effectiveness.
Pregnancy and Lactation: Acyclovir is generally considered safe for use during pregnancy and lactation when clinically indicated. However, healthcare professionals may consider the potential risks and benefits of treatment on a case-by-case basis, particularly in pregnant women with severe or recurrent herpes infections.
Prevention of Transmission: While acyclovir helps alleviate symptoms and shorten the duration of herpes outbreaks, it does not cure the underlying viral infection or prevent transmission to others. Patients should be advised to practice safe sex and use barrier methods to reduce the risk of transmitting genital herpes to sexual partners.
(Aciclovir, ACV)
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
Taxonomy | Rank | Effect | Citations | Notation |
---|---|---|---|---|
Agathobacter | genus | Decreases | πͺ Source Study | |
Agathobacter rectalis | species | Decreases | π Source Study | |
Blautia | genus | Decreases | πͺ Source Study | |
Blautia obeum | species | Decreases | π Source Study | |
Coprococcus | genus | Decreases | πͺ Source Study | |
Coprococcus comes | species | Decreases | π Source Study | |
Lachnospira | genus | Decreases | πͺ Source Study | |
Lachnospira eligens | species | Decreases | π Source Study | |
Staphylococcus | genus | Decreases | πͺ Source Study | |
Staphylococcus aureus | species | Decreases | π Source Study | Skin infections, sinusitis, food poisoning |
Staphylococcus aureus 04-02981 | strain | Decreases | πΆ Source Study | |
Staphylococcus aureus 07-03450 | strain | Decreases | πΆ Source Study | |
Staphylococcus aureus 07-03451 | strain | Decreases | πΆ Source Study | |
Staphylococcus aureus 08-01059 | strain | Decreases | πΆ Source Study | |
Staphylococcus aureus 08-01062 | strain | Decreases | πΆ Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive β X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.8 | 0.8 | |
ADHD | 1.1 | 0.3 | 2.67 |
Allergic Rhinitis (Hay Fever) | 0.9 | 0.3 | 2 |
Allergies | 0.7 | 0.5 | 0.4 |
Allergy to milk products | 0.3 | 0.3 | |
Alopecia (Hair Loss) | 0.1 | 0.1 | |
Alzheimer's disease | 0.1 | 1.5 | -14 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.8 | |
Ankylosing spondylitis | 1.2 | 0.3 | 3 |
Anorexia Nervosa | 0.4 | 1 | -1.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [216.73.216 ]